LA JOLLA, Calif., June 20, 2011 /PRNewswire/ -- Anaphore Inc. today announced the appointment of Paul A. Grayson as president and CEO. A life sciences executive with an extensive track record of success in business development and financial transactions for emerging biopharmaceutical companies, Grayson joins Anaphore as it focuses its efforts on the establishment of collaborations with pharmaceutical companies for the discovery and development of novel Atrimer therapeutics. He replaces Katherine S. Bowdish, Ph.D., a co-founder of Anaphore, who will continue to serve the company as a consultant.
"I am proud of the collective accomplishments of the Anaphore team from inception to date including significantly advancing the core platform technology, programs, and forging a critical partnership," said Kathy Bowdish. "I am confident of the team's ability to execute under Paul's direction as the company embarks in this next exciting stage in its evolution."
"The addition of Paul reflects Anaphore's movement into its next phase of development," said Russell G. Greig, Ph.D., the company's executive chairman. "His deal-making experience and leadership qualities will bring a new dimension to the company as we increase our efforts to unlock the value of our technology platform. We are grateful to Kathy for her success in building a top-notch scientific team and advancing the technology to this sophisticated stage."
Grayson commented, "I've had the opportunity to evaluate many leadership opportunities in the industry over the past months. Anaphore's Atrimer technology caught my attention and stood out as an innovative approach to tackling diseases that were out of reach because of limitations with today's protein drugs. I am excited to join the company at its current stage and view this as an opportunity that is destined for success."
Grayson previously served as CEO of Fate Therapeutics, a San Diego-based, privately held
Copyright©2010 PR Newswire.
All rights reserved